Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

by · The Markets Daily

Research analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research report issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 0.7 %

Shares of Akari Therapeutics stock opened at $2.98 on Tuesday. The business has a 50-day moving average price of $3.48 and a two-hundred day moving average price of $2.63. Akari Therapeutics has a 1-year low of $1.08 and a 1-year high of $4.40.

Akari Therapeutics Company Profile

(Get Free Report)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.

See Also